Latest Market Expansion News

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Centrex Limited stabilises operations at Ardmore Mine, completes Australia’s first phosphate export to India, and launches a $10.4 million entitlement offer to fund expansion.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Live Verdure Ltd has secured a controlling stake in AI innovator Decidr.ai and reported robust e-commerce growth for its Edible Beauty brand, underscoring its strategic pivot towards AI-driven expansion.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

BirdDog Technology reports a strategic pivot with four next-generation product launches, a 20% price increase, and a robust cash position, despite a 13% revenue decline in H1 FY25.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

Volt Group Limited reported a robust 20% increase in FY24 revenue receipts, driven by strong EcoQuip growth and strategic contract wins, while advancing its zero-emission ATEN technology with promising trials underway.

First Graphene Limited reports a robust December quarter with new patents, expanded distribution networks, and advancing commercial trials, positioning the company on a path to cash breakeven.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.